| Table 1. Top 100 Drugs by Sales | ||
| Rank | Drug (Brand Name) | Sales Through March 2014 |
| 1 | Abilify | $6,885,243,368 |
| 2 | Nexium | $6,271,376,299 |
| 3 | Humira | $5,936,288,498 |
| 4 | Crestor | $5,502,148,010 |
| 5 | Advair Diskus | $5,112,576,549 |
| 6 | Enbrel | $4,896,267,318 |
| 7 | Remicade | $4,235,535,358 |
| 8 | Cymbalta | $4,095,537,942 |
| 9 | Copaxone | $3,679,837,035 |
| 10 | Neulasta | $3,634,919,067 |
| 11 | Lantus Solostar | $3,375,632,862 |
| 12 | Rituxan | $3,320,475,967 |
| 13 | Spiriva Handihaler | $3,140,602,715 |
| 14 | Januvia | $2,975,320,499 |
| 15 | Atripla | $2,894,627,347 |
| 16 | Lantus | $2,796,784,267 |
| 17 | Avastin | $2,742,284,655 |
| 18 | Lyrica | $2,611,451,728 |
| 19 | Oxycontin | $2,528,601,587 |
| 20 | Epogen | $2,346,224,521 |
| 21 | Celebrex | $2,342,549,444 |
| 22 | Truvada | $2,307,970,304 |
| 23 | Diovan | $2,190,542,692 |
| 24 | Gleevec | $1,995,042,989 |
| 25 | Herceptin | $1,971,724,243 |
| 26 | Lucentis | $1,917,919,037 |
| 27 | Namenda | $1,871,956,353 |
| 28 | Vyvanse | $1,848,814,801 |
| 29 | Zetia | $1,826,260,072 |
| 30 | Levemir | $1,775,037,064 |
| 31 | Symbicort | $1,733,830,589 |
| 32 | Sovaldi | $1,724,867,241 |
| 33 | Novolog Flexpen | $1,482,659,229 |
| 34 | Novolog | $1,409,680,368 |
| 35 | Tecfidera | $1,394,704,148 |
| 36 | Suboxone | $1,388,805,102 |
| 37 | Humalog | $1,310,236,982 |
| 38 | Xarelto | $1,263,697,546 |
| 39 | Seroquel XR | $1,251,615,894 |
| 40 | Viagra | $1,235,125,299 |
| 41 | Alimta | $1,205,717,422 |
| 42 | Victoza 3-Pak | $1,186,784,355 |
| 43 | Avonex | $1,184,476,004 |
| 44 | Nasonex | $1,180,165,756 |
| 45 | Cialis | $1,170,843,904 |
| 46 | Gilenya | $1,097,409,827 |
| 47 | Stelara | $1,083,660,282 |
| 48 | Flovent HFA | $1,078,422,967 |
| 49 | Prezista | $1,046,464,870 |
| 50 | Procrit | $1,037,298,436 |
| 51 | Isentress | $1,037,220,122 |
| 52 | Janumet | $1,028,179,032 |
| 53 | Renvela | $1,023,751,529 |
| 54 | Humalog Kwikpen | $1,003,100,788 |
| 55 | Orencia | $990,449,529 |
| 56 | Dexilant | $967,408,551 |
| 57 | Vesicare | $967,408,277 |
| 58 | Neupogen | $944,389,150 |
| 59 | Reyataz | $935,417,307 |
| 60 | Lunesta | $927,689,337 |
| 61 | Synthroid | $899,215,664 |
| 62 | Pradaxa | $862,604,444 |
| 63 | Zytiga | $861,683,197 |
| 64 | Benicar | $860,761,655 |
| 65 | Xolair | $859,052,353 |
| 66 | Avonex Pen | $849,256,894 |
| 67 | Vytorin | $846,602,646 |
| 68 | Invega Sustenna | $831,061,694 |
| 69 | Sensipar | $824,871,721 |
| 70 | Xgeva | $822,603,435 |
| 71 | Prevnar 13 | $821,372,081 |
| 72 | Evista | $815,315,970 |
| 73 | Aranesp | $814,017,366 |
| 74 | Betaseron | $792,093,855 |
| 75 | Stribild | $785,645,319 |
| 76 | Combivent Respimat | $768,925,543 |
| 77 | Xeloda | $761,832,629 |
| 78 | Afinitor | $761,796,538 |
| 79 | Ventolin HFA | $761,324,992 |
| 80 | Synagis | $755,220,544 |
| 81 | Zyvox | $732,206,096 |
| 82 | Bystolic | $719,917,435 |
| 83 | Sandostatin LAR | $708,264,105 |
| 84 | Complera | $696,270,123 |
| 85 | Benicar HCT | $692,128,910 |
| 86 | Treanda | $691,670,874 |
| 87 | Gardasil | $683,558,728 |
| 88 | Zostavax | $679,653,129 |
| 89 | Pristiq | $660,397,547 |
| 90 | Erbitux | $660,368,777 |
| 91 | Focalin XR | $647,720,027 |
| 92 | Tarceva | $646,108,218 |
| 93 | Cubicin | $643,649,546 |
| 94 | Strattera | $640,562,124 |
| 95 | Latuda | $639,903,393 |
| 96 | Velcade | $624,619,639 |
| 97 | Viread | $606,046,798 |
| 98 | Welchol | $603,644,260 |
| 99 | Nuvaring | $600,191,343 |
| 100 | Sprycel | $599,882,414 |
| Source: IMS National Prescription Audit, IMS Health. | ||
Régénération tissulaire médiée par les cellules souches au cours du vieillissement: Perspectives cellulaires et moléculaires
Régénération tissulaire médiée par les cellules souches au cours du vieillissement: Perspectives cellulaires et moléculaires Résumé Le vieillissement s'accompagne d'un déclin fonctionnel progressif dans pratiquement tous les tissus. La biologie régénérative moderne étudie si les stratégies basées sur les cellules souches peuvent restaurer l'intégrité structurelle et les performances physiologiques Lire la suite
